phenoxodiol (NV06) / MEI - LARVOL DELTA

Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617. (PubMed, Eur Urol Open Sci) - "ctDNA from men treated with Lu-PSMA in combination with idronoxil for progressive mCRPC were analysed using an 85-gene customised sequencing assay. Certain DNA/gene changes detected in the blood of men with advanced prostate cancer were associated with shorter benefit from lutetium PSMA, a targeted radioactive therapy. This information may be useful in determining which men may benefit most from this treatment, but additional research is needed."

Biomarker • Circulating tumor DNA • Journal • Metastases • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Characterization of the Prognosis and Tumor Microenvironment of Cellular Senescence-related Genes through scRNA-Seq and Bulk RNA-Seq Analysis in GC. (PubMed, Recent Pat Anticancer Drug Discov) - "The two molecular subtypes, with their own individual OS rate, expression patterns, and immune infiltration, lay the foundation for further exploration into the GC molecular mechanism. The eight gene signatures could effectively predict the GC prognosis and can serve as reliable markers for GC patients."

Biomarker • IO biomarker • Journal • Tumor microenvironment • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Pharmacological inhibition of TBK1/IKKε blunts immunopathology in a murine model of SARS-CoV-2 infection. (PubMed, Nat Commun) - "Treatment with idronoxil, or the small molecule inhibitor MRT67307, suppresses TBK1/IKKε signalling and attenuates cellular and molecular lung inflammation in SARS-CoV-2-challenged mice. Our findings additionally demonstrate that engagement of STING is not the major driver of these inflammatory responses and establish a critical role for TBK1/IKKε signalling in SARS-CoV-2 hyper-inflammation."

Journal • Preclinical • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • STING

ENOX2 inhibition enhances infiltration of effector memory T-cell and mediates response to chemotherapy in immune-quiescent cancer. (PubMed, J Adv Res) - "Tumor-intrinsic ENOX2 expression is associated with tumor phenotype and PFS in NPC. Targeting ENOX2 with IDX and cisplatin impose qualitative control of T-cell response by preferentially increasing immune cells infiltration, Tem differentiation and tumor suppression. We suggest that ENOX2 inhibition may be a promising therapeutic strategy to enhance the effects of chemotherapy."

Journal • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • CD8

The role of isoflavones in augmenting the effects of radiotherapy. (PubMed, Front Oncol) - "Currently ongoing clinical research explores a potential of another significant isoflavone, idronoxil, also known as phenoxodiol, as radiation enhancing agent. This review discusses important aspects of the development of isoflavones as anticancer agents, and mechanisms potentially relevant to their activity in combination with radiation therapy of cancer. It gives a critical overview of studies characterizing isoflavone targets such as topoisomerases, ENOX2/PMET, tyrosine kinases and ER receptor signaling, and cellular effects on the cell cycle, DNA damage, cell death, and immune responses."

Journal • Review • Cardiovascular • Genito-urinary Cancer • Heart Failure • Oncology • Prostate Cancer • Solid Tumor

Chemosensitization of carboplatin by NOX66: Pharmacokinetics and safety (ESMO 2017) - P2a; "...This first-in-human study will look at the ability of NOX66 to deliver relatively high levels of idronoxil in a bio-active form, investigating (a) PK and (b) safety of NOX66 administration both as a monotherapy and in combination with carboplatin...Patients included have end stage, refactory solid tumours, and no further therapy options available...Subject to safety review, standard dose (AUC6) carboplatin is administered for cycles 4-6. Safety assessment is continued throughout the study, with measures to identify efficacy signals (CT scan, ECOG) performed at baseline and after Cycles 3 and 6."

Ovarian Cancer

NOX66 plus carboplatin - a phase 1 signalling study (ESMO Asia 2017) - P2a; "Patients (16) with end stage, refactory solid tumours, and no further therapy options available, were allocated to one of two treatment cohorts, receiving NOX66 at a dose of 400mg or 800mg of idronoxil daily. NOX66 in combination with carboplatin is well tolerated, with efficacy data for patients receiving low dose-low dose combination therapy providing evidence to suggest that NOX66 may sensitize end stage solid tumours to chemotherapy."

Combination therapy • Late-breaking abstract • P1 data • Solid Tumor

Isoflavonoid-based therapeutics to remodel immunologically cold tumors in nasopharyngeal carcinoma. (ASCO 2022) - "We aimed at delineating and defining the contribution of idronoxil (IDX), a synthetic flavonoid derivative, in restoring sensitivity to apoptosis and potentially modulating the immune microenvironment of NPC...In vitro, we observed increased migration of T cells towards cancer cells when tumor cells were pre-treated with the combination of IDX and cisplatin (IDX+Cis) compared with monotherapy (IDX or cis alone) or untreated... Distinct immunospatial profiles could be associated with clinicopathologic characteristics. The ability of IDX to modulate T cell populations indicates the potential of IDX to enhance the efficacy of current chemotherapy treatments in NPC by upregulating cellular trafficking toward tumor."

Immunology • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • CD8

The potential anti-amyloidogenic candidate, SPA1413, for Alzheimer's disease. (PubMed, Br J Pharmacol) - "Our results strongly support the repurposing potential of SPA1413, which received a fast track status from the US-FDA for cancer treatment, targeting the anti-amyloidogenic and anti-neuroinflammatory activities for Alzheimer's disease."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Immunology • Inflammation • Oncology

[VIRTUAL] Idronoxil combined with cisplatin rescues refractory immune responses in nasopharyngeal carcinoma (COSA 2020) - "Conclusions : IDX was shown to induce apoptosis in NPC cells while inhibiting their migration. Moreover, the ability of IDX to modulate T cell populations indicates the drug’s potential to enhance the efficacy of current chemotherapy treatments in NPC by upregulating cellular trafficking to the cancer cell."

Nasopharyngeal Carcinoma • Oncology • Solid Tumor

[VIRTUAL] Effect of idronoxil combined with cisplatin on refractory immune responses in nasopharyngeal carcinoma. (ASCO 2020) - "IDX was shown to induce apoptosis in NPC cells while inhibiting their migration and proliferation. Moreover, the ability of IDX to modulate T cell populations indicates the drug’s potential to enhance the efficacy of current chemotherapy treatments in NPC by upregulating cellular trafficking to the cancer cell. Research Funding: Bridging grant from Australian Academy of Technology & Engineering"

Nasopharyngeal Carcinoma • Oncology • Solid Tumor • CD8 • GZMB

Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: Royal North Shore Hospital; Not yet recruiting ➔ Recruiting; Initiation date: Apr 2017 ➔ Aug 2017; Trial primary completion date: Mar 2018 ➔ Sep 2018

Enrollment open • Trial initiation date • Trial primary completion date • Biosimilar • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

"Noxopharm Collaborates with GenesisCare to Bring Combination Regimen of Veyonda (idronoxil) and Lu-PSMA in Australia @noxopharm @GenesisCare https://t.co/JjkdbyDWxm" (@Pharmashot)

Idronoxil as an Anticancer Agent: Activity and Mechanisms. (PubMed, Curr Cancer Drug Targets) - "Whilst clinically tested in the past, idronoxil's journey was discontinued as a result of its low bioavailability in humans when administered either intravenously or orally, though strategies to overcome this issue are currently being explored. Here, we summarize the current literature regarding the key cellular targets of idronoxil and the mechanisms by which idronoxil exerts its anticancer effects, laying a new foundation toward giving this unique molecule a second chance at contributing to the future of cancer treatment."

Journal